0001052918-21-000246.txt : 20210628 0001052918-21-000246.hdr.sgml : 20210628 20210628165441 ACCESSION NUMBER: 0001052918-21-000246 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20210131 FILED AS OF DATE: 20210628 DATE AS OF CHANGE: 20210628 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Avricore Health Inc. CENTRAL INDEX KEY: 0001355736 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51848 FILM NUMBER: 211054191 BUSINESS ADDRESS: STREET 1: 789 WEST PENDER STREET STREET 2: SUITE 810 CITY: VANCOUVER STATE: A1 ZIP: V6C 1H2 BUSINESS PHONE: 604-687-2038 MAIL ADDRESS: STREET 1: 789 WEST PENDER STREET STREET 2: SUITE 810 CITY: VANCOUVER STATE: A1 ZIP: V6C 1H2 FORMER COMPANY: FORMER CONFORMED NAME: Vanc Pharmaceuticals Inc. DATE OF NAME CHANGE: 20140911 FORMER COMPANY: FORMER CONFORMED NAME: NUVA Pharmaceuticals Inc. DATE OF NAME CHANGE: 20140110 FORMER COMPANY: FORMER CONFORMED NAME: ALDA Pharmaceuticals Corp. DATE OF NAME CHANGE: 20060309 6-K 1 avricore6kjan2021.htm AVRICORE HEALTH INC. Avricore Health Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549 

 

 

FORM 6-K

 

 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15b-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of: January 2021

 

Commission File Number:  000-51848

 

 

Avricore Health Inc.

(Exact name of registrant as specified in its charter)

 

N/A

(Translation of Registrant’s name into English)

 

3500 – 1055 Dunsmuir Street PO Box 49114 Vancouver BC V7X1H7

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.      Form 20-F x Form 40-F o

 

Indicate by check mark if the Registrant is submitting this Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):    Yes o No x

 

Indicate by check mark if the Registrant is submitting this Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   Yes o No x

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form 6-K is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:    Yes o No x

 

 

Exhibits

 

The following exhibits are included in this Form 6-K:

 

Exhibit No.

Description

Date filed on SEDAR

99.1

News Release, Avricore’s Healthtab Expands North with Oak Medical Arts, December 3, 2020

January 28, 2021

99.2

News Release, Avricore Health Announces Board of Directors Change, New Advisor, December 10, 2020

January 28, 2021

99.3

News Release, Avricore health Successfully integrates ID NOWTM Rapid PCR Test Device, Offering Real-Time Covid 19 Reporting Direct from Instrument for First Time, December 14, 2020

January 28, 2021

99.4

News Release, Avricore Health Completes $1.5 Million Financing, January 26, 2021

January 26, 2021

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Dated:  June 28, 2021

AVRICORE HEALTH INC.

 

 

 

By: /s/ Kiki Smith

 

Kiki Smith

 

Chief Financial Officer

2

 EX-99.1 2 nr_ex99z1.htm EXHIBIT 99.1 Exhibit 99.1

Exhibit 99.1

Picture 1 

AVRICORE’S HEALTHTAB EXPANDS NORTH WITH OAK MEDICAL ARTS

VANCOUVER, BC – (GLOBE NEWSWIRE) – December 3rd, 2020 – Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to announce it will be placing its real-time reporting HealthTabÔ systems in Oak Medical Art’s community pharmacy locations, bringing advanced point of care testing to Canada’s North for the first time.

 

“HealthTabÔ offers affordable screening solutions to communities where it just wasn’t possible before.”   said Avricore Health’s CEO, Hector Bremner. “We think that everyone deserves access to healthcare data we’re so happy to officially reach Canada’s north!”

 

Pharmacies agree to a two-year lease commitment, as well as the purchase of reagent panels and other consumables from the Company.  De-identified, statistical data can also be monetized, presenting additional revenue streams for the Company.

 

“Oak Medical Arts prides itself on innovation and putting patients at the center of everything we do.” Said Bryan Gray, Director of Oak Medical Arts. “By offering point-of-care testing to better understand our patient needs, we can deliver better service and support better health outcomes.”

 

About HealthTabÔ + RASTR

 

HealthTabÔ is a proven point-of-care screening system, designed to support pharmacists evolving role. The system empowers patients to be proactive about their health by directly measuring and monitoring key safety tests and biomarkers of chronic disease. The HealthTabÔ  test is simple, fast, lab-accurate, and requires just a few drops of blood from a finger stick.  Results can be printed in-store or accessed securely online.

 

Typically, HealthTab™ utilizes the Piccolo Xpress, an Abaxis Global Diagnostics chemistry analyzer, however, the system is designed to interface with other devices and third-party applications.

 

As part of this direction for HealthTabÔ, the Company developed a revolutionary model for utilizing the system’s unique ability to offer real-time evaluations of treated populations and even real-world evaluation clinical trials.

 

The name for this approach is Rapid Access Safety Test Reporting, or RASTR Network, whereby the network of HealthTabÔ systems feedback de-identified data through to electronic health records and data management systems via its API capabilities.  This is the first platform of harmonized analyzers, with fully integrated data-flow, for blood chemistry results to be sent to consumers, their healthcare teams and sponsors; such as researchers, insurance providers and the life-science sector.

 

The significance of this approach to the market is the enhanced access to screening and early detection of disease, better data for physicians and pharmacists to support their patients, plus new opportunities to conduct research and ensure patient safety.  

 

About Avricore Health Inc.

Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level. The Company's goal is to empower consumers, patients and pharmacists with innovative technology, products, services and information to monitor and optimize health. www.avricorehealth.com

 

Contact:

 

Hector Bremner, CEO 604-773-8943
info@avricorehealth.com 
www.avricorehealth.com 

 

Cautionary Note Regarding Forward-Looking Statements

Information in this press release that involves Avricore Health's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

 EX-99.2 3 nr_ex99z2.htm EXHIBIT 99.2 Exhibit 99.2

Exhibit 99.2

Picture 1 

 

AVRICORE HEALTH ANNOUNCES BOARD OF DIRECTORS CHANGE, NEW ADVISOR

 

The Company welcomes CTO Rodger Seccombe, co-creator of HealthTab to the Board and thanks Bobby Rai for his service and leadership on the Board of Directors and as President as he takes an advisory role.

 

 

VANCOUVER, BRITISH COLUMBIA – December 10, 2020 – AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) announces changes to its board of directors today as the Company continues to make significant progress towards its objective of bringing comprehensive point-of-care testing and reporting solutions for chronic disease and viral infection, including COVID-19, to community pharmacies around the world.

 

The Board extends a warm welcome to the Company’s CTO and co-founder of HealthTab™, Rodger Seccombe.  

 

“I’m really glad to welcome Rodger to the Board, as he has been such an integral part of the team and important driver of our success” said Board Chair, David Hall. “We look forward to having his perspective at the table as we execute our plans for growth in 2021.”

 

Mr. Seccombe brings over 20 years of experience in software and technology, as well as clean energy, having successfully developed and sold multiple ventures throughout his career. In 2014, Mr. Seccombe launched a cloud-based informatics system currently being used by some of the largest medical laboratory networks and instrument manufacturers in North America to help monitor and improve the accuracy of their testing. After recognizing the need for more accurate and accessible point-of-care testing services in the community, Mr. Seccombe, along with his brother, created and pioneered HealthTab™, which was later acquired by Avricore Health in 2017.

 

Resigning from the board and as President, is Bobby Rai, who led the Company through its transition to become Avricore Health from its previous iteration as a cross-licence drug maker. Mr. Rai demonstrated great vision and tenacity in setting Avricore Health on its path to becoming a world leader in bringing innovations to pharmacy, such as the Company’s point-of-care data sharing technology, HealthTab™.

 

In 2019, Mr. Rai took the role as President to support the transition of new CEO Hector Bremner, and today, now that this transition is fully executed, he takes a role on the Company’s Advisory Board.

 

Also joining the Advisory Board is Dr. Sanjeev Goel, founder of Peak Human and practicing physician with Kennedy Medical Centre.  Dr. Goel promotes healthy lifestyles through plant-based diets, physical activity, mental health and regenerative medicine. Dr. Goel also works with indigenous communities in Ontario to bring quality medical practice to those communities.

 

The Company has granted stock options to purchase up to 710,000 common shares of the Company pursuant to its Stock Option Plan to various officers of the Company. Each option is exercisable for a period of five years at an exercise price of $0.08 per common share, subject to regulatory regulations.

 

 

About HealthTabÔ + RASTR

 

HealthTab™ is a proven point-of-care screening system, designed to support pharmacists evolving role. The system empowers patients to be proactive about their health by directly measuring and monitoring key safety tests and biomarkers of chronic disease. The HealthTab™ test is simple, fast, lab-accurate, and requires just a few drops of blood from a finger stick.  Results can be printed in-store or accessed securely online.

Typically, HealthTab™ utilizes the Piccolo Xpress, an Abaxis Global Diagnostics chemistry analyzer, however, the system is designed to interface with other devices and third-party applications.

 

As part of this direction for HealthTab™, the Company developed a revolutionary model for utilizing the system’s unique ability to offer real-time evaluations of treated populations and even real-world evaluation clinical trials.

 

The name for this approach is Rapid Access Safety Test Reporting, or RASTR Network, whereby the network of HealthTab™ systems feedback de-identified data through to electronic health records and data management systems via its API capabilities.  This is the first platform of harmonized analyzers, with fully integrated data-flow, for blood chemistry results to be sent to consumers, their healthcare teams and sponsors; such as researchers, insurance providers and the life-science sector.

 

The significance of this approach to the market is the enhanced access to screening and early detection of disease, better data for physicians and pharmacists to support their patients, plus new opportunities to conduct research and ensure patient safety.  

 

 

About Avricore Health Inc.

 

Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level. The Company's goal is to empower consumers, patients and pharmacists with innovative technology, products, services and information to monitor and optimize health. www.avricorehealth.com

 

 

Contact:

 

Hector Bremner, CEO 604-773-8943
info@avricorehealth.com 
www.avricorehealth.com 

 

Cautionary Note Regarding Forward-Looking Statements

Information in this press release that involves Avricore Health's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 EX-99.3 4 nr_ex99z3.htm EXHIBIT 99.3 Exhibit 99.3

Exhibit 99.3

Picture 1 

AVRICORE HEALTH SUCCESSFULLY INTEGRATES ID NOW™ RAPID PCR TEST DEVICE, OFFERING REAL-TIME COVID-19 REPORTING DIRECT FROM INSTRUMENT FOR FIRST TIME.

 

Earlier this fall, the Company announced a joint working agreement to integrate a major manufacturer’s devices with its HealthTab™ data reporting platform for deployment in Canada, resulting in new testing capabilities, including COVID-19 molecular PCR results via the ID Now™.

 

VANCOUVER, BRITISH COLUMBIA – December 14, 2020 – AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is pleased to announce that its engineering team, led by Chief Technology Officer, Rodger Seccombe, have successfully integrated its real-time reporting platform HealthTab™ and the ID Now™, a molecular PCR point-of-care device manufactured by Abbott Diagnostics.

 

The Company will now offer to jurisdictions deploying these devices the only real-time reporting platform capable of securely transmitting COVID-19 test results automatically from the instrument to patients, healthcare teams and key agencies, significantly increasing the speed and accuracy of information sharing and reducing workload. HealthtabTM features a patient facing web-portal as well as the ability for direct integration of data into COVID-19 contact tracing apps already deployed.  Healthcare teams and agencies can receive real-time case reporting to streamline contact tracing, identify outbreaks and better deploy resources.

 

“Thanks to the technical team at the manufacturer, we were able to build and test this interface quickly and seamlessly,” said Rodger Seccombe, Avricore Health’s CTO. ‘We’re excited to be able to offer an automated point-of-care data management solution for community-based testing sites that don’t have the information systems or technical resources you find in a hospital or medical laboratory.

 

The Company hopes to secure agreements with jurisdictions deploying the approximately 3800 ID Now™ devices and more than 8 million tests being supplied by the Government of Canada. The devices and tests are expected to add testing capacity within rural and Indigenous communities, long-term care facilities and hospitals as they can conduct high-quality molecular tests onsite.

 

“The combination of high-quality instruments and real-time reporting makes point-of-care test deployment faster and more reliable than ever,” said Avricore Health CEO, Hector Bremner. “We’ve been hearing from those on the frontlines that this is overdue, and we are really proud to now offer this critical service.”

 

The HealthtabTM web-enabling hardware and software as a service reporting system is available for a monthly licencing fee. The Company is embarking on its marketing and awareness efforts with health regions and hopes to see systems deployed in the near future.

 

The Company is proceeding with the $874,000 second tranche of its previously announced non-brokered private placement. The second tranche is comprised of up to 8,740,000 units at $0.10 per unit for gross proceeds of up to $874,000. Each Unit consists of one common share and one transferrable share purchase warrant. Each warrant will entitle the holder thereof to purchase one additional common share for a period of 12 months from the closing date of the offering at a price of $0.15 per common share provided that if the closing price of the common shares of the Company on any stock exchange or quotation system on which the common shares are then listed or quoted is equal to or greater than $0.20 for a period of fifteen (15) consecutive trading days, the Company will have the right to accelerate the expiry of the warrants to a date that is not less than ten (10) business days from the date notice is given. The Company may pay finders fees of up to 5% cash and 5% finders warrants on a portion of the placement. Refer to the Company’s news release of October 14, 2020 for additional details.

About HealthTabÔ + RASTR

 

HealthTab™ is a proven point-of-care screening system, designed to support pharmacists evolving role. The system empowers patients to be proactive about their health by directly measuring and monitoring key safety tests and biomarkers of chronic disease. The HealthTab™ test is simple, fast, lab-accurate, and requires just a few drops of blood from a finger stick.  Results can be printed in-store or accessed securely online.

 

Typically, HealthTab™ utilizes the Piccolo Xpress, an Abaxis Global Diagnostics chemistry analyzer, however, the system is designed to interface with other devices and third-party applications.

 

As part of this direction for HealthTab™, the Company developed a revolutionary model for utilizing the system’s unique ability to offer real-time evaluations of treated populations and even real-world evaluation clinical trials.

 

The name for this approach is Rapid Access Safety Test Reporting, or RASTR Network, whereby the network of HealthTab™ systems feedback de-identified data through to electronic health records and data management systems via its API capabilities.  This is the first platform of harmonized analyzers, with fully integrated data-flow, for blood chemistry results to be sent to consumers, their healthcare teams and sponsors; such as researchers, insurance providers and the life-science sector.

 

The significance of this approach to the market is the enhanced access to screening and early detection of disease, better data for physicians and pharmacists to support their patients, plus new opportunities to conduct research and ensure patient safety.  

 

About Avricore Health Inc.

 

Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level. The Company's goal is to empower consumers, patients and pharmacists with innovative technology, products, services and information to monitor and optimize health. www.avricorehealth.com

 

Contact:

 

Hector Bremner, CEO 604-773-8943
info@avricorehealth.com 
www.avricorehealth.com 

 

Cautionary Note Regarding Forward-Looking Statements

Information in this press release that involves Avricore Health's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

EX-99.4 5 nr_ex99z4.htm EXHIBIT 99.4 Exhibit 99.4

Exhibit 99.4

Picture 1 

 

AVRICORE HEALTH COMPLETES $1.5 MILLION FINANCING

 

Vancouver, British Columbia – January 26, 2021 – AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) announces it has closed the final tranche of its non-brokered private placement for gross proceeds of $874,000 to complete its $1.5 million financing. The Company will issue 8,740,000 units at $0.10 per unit and will pay finders fees totaling $29,050 and issue 290,500 finders warrants. Insiders participated in the aggregate amount of $88,000 for 880,000 units. Placement proceeds will be used for general working capital purposes.  

 

“We are honoured to have had this level of support in challenging times.”  Said Hector Bremner, CEO of Avricore Health. “It demonstrates the strong sentiment and belief in our mission, and our team. We look forward to now delivering on our work and expanding HealthTab™ to more pharmacies and other applications."

 

Each Unit consists of one common share and one transferrable share purchase warrant. Each warrant will entitle the holder thereof to purchase one additional common share for a period of 12 months from the closing date of the offering at a price of $0.15 per common share provided that if the closing price of the common shares of the Company on any stock exchange or quotation system on which the common shares are then listed or quoted is equal to or greater than $0.20 for a period of fifteen (15) consecutive trading days, the Company will have the right to accelerate the expiry of the warrants to a date that is not less than ten (10) business days from the date notice is given.

 

Closing of the Private Placement is subject to final acceptance by the TSX Venture Exchange. All securities issued in connection with the Private Placement will be subject to a four-month hold period from the closing date under applicable Canadian securities laws.

 

The Private Placement securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "1933 Act"), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.

 

Contact:

 

Hector Bremner, CEO 604-773-8943

info@avricorehealth.com 

www.avricorehealth.com 

 

 

About Avricore Health Inc.

 

Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level. The Company's goal is to empower consumers, patients and pharmacists with innovative technology, products, services and information to monitor and optimize health. www.avricorehealth.com

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

GRAPHIC 6 nrex99z1_1.jpg IMAGE begin 644 nrex99z1_1.jpg M_]C_X 02D9)1@ ! 0( #@ H #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ JA MJ>L66D0>;=3*.1@9'//.?:LV'P MQ;:4G]J>*K@2+)P8AO=BY]6!ZUZ5' I14Z[M?9+=GDU\Q;DZ>'2=MY-VBOF; MVD^.8-8UN+3X;*1%EW8D=QGA2>@^GK2>)?$>L:5?+#864QIU#-&FNYYVD1B-SJIY!8[< GC[PK3T/7;77K(7%N'0@E71 MQRI&._0]17C5*#5YT[N"=KV/?I8A/EA4LIM7M>YJ4445SG2%%%->18EW.<"@ M!U%1QS1R_<;./:I* "BBB@ HHJMJ%Y'IVFW5]*"8[:%YF"]2%!)Q^5 %FBO! M/#7Q\N]8\9V-A<:4T=I?7,5NJK.K&(M\N?N D;B#UKWN@ HHHH **** "BBB M@ HHHH **** "LS4M>T_2;J"WO)61Y_N80D=0.AQ- MXL\4W-]?,9;:V^==QP%&_*J?;&[BNS"8>-12G4?NQ7_#'!C<5.DX4Z2O*3TO MY;F[>6FA^#99-1>V$DDYQ!&%)VL,MU)./X>>V*P=.T.]U\G6M;NB+%LLNYBQ M;)VX 4_* 0/3M75:UX=M?$EW:78N_-BB(#JLHV%,Y.,#J?KZ5RE[/?>,=:?2 M]/=1IMN28P!L0*!@$XSWZ?7M7I86HY0NI>];WI/HNR\V>3BZ:A/EDRO/)"&Y&Z1$_0 M=/RI482IQI&K-0ASZ+54_A3ZZD4FM^+= VOJH+PGY0K-$3G MZ@$U.I\/^,U^RV]L-.U-OGWB+(..HRI&>!WQ71^+M8O-&T^&:TMUFW28DWQE MD"X/7!&.<8KF+S3-*\2Z>;SP]&(M30AIH%.S@\'CI[\'ZU5&<9P55QY&_M1V M_P"WEV%7IRISE04_:):\LMVO[K[^A7T_5+OPGJ4NF:SNN;$+L$8(=1CY@0#V MYZ<=?:M;3O"][9^*X]2TR6--+E_> @D91N=FT\_Y[&JVFSCQCI#Z/J!_XF5J M R2N-K<-AN>>V >/\:U]#L-,J,C/?/X48BHX*6T M9O22Z-/[2%A:2FX[R@O>B^J:^RV=917$>"=9NFOKO1]0F>2YC>1]TAR<@J", MD^NXUV]>/B*$J%1PD>]A<3'$TU4CH%?./[0OBR2?5X_"L1?R(%BN9N<#S"'X MQCGY64]?PKW_ %K5(-$T.^U2Y<+#:0/,Q/\ L@G'N3TQWKY0TC?\0_C=%/*# M<07FI&=PWR_Z.AW8/H B@?I6!T#_ (*:\=$^)>GQN[B"_#6CJO3+XV\?[RK7 MO_C3XL:'X$UB+3-5LM3EEE@$Z/;1QLI4DC^)P] 'LVG>+-,U3P@WBBV,QTT0RS$LF'VQE@W'_ #7&Z!\6C2Q1!1WR2)"< #T->+Z'\0%T[X,:WX6:Y9;V>8BV4(>(G M*;US[CS/SKN?V=O"L$EK?>);NU#3).(;*5NJX1A(5]B' S[>U ':/\;O"D/B M!M(N8=2MW0%GG>!3&H";_P"%RW3CA>OYT_0_C'X7\5ZN=&L[349#)&Y+30(( MV41L[ _/GHI'3_&OF[Q1;?;/B!+:YQYTL,>?3*H/ZU])Z3\)/"_A%I=3TU;P MW<,,NUYI]PY1E.1@#HQH \_\&ZU\);WQWIZZ1X7U.'4)9D^R-,/W<,@!^8CS MF'H?NG!&>M>P>+O'&B>"+);G6)9@TBL8H88B[R8(! _A'WAU(KY4^%?_ "5' MP]_U]C^1K:^(EU/XL^,J65[,\4$DUK:1B0[!"CA,]#/^$"=$\4O#XFT+ M58ELFNHX-*O/M#1RHK88KM&,\#WP/2@#L_&GQ>\/>"KU;"YBO+N]*EC%!& % M&2.68@=5(XS6%HO[0GA?4;L6]]9W^GEV"I(RB1#DXYVG(Z^AZ&O)?A'X1T_Q M]XPOH]>EEFCB@-RRB8J\SF1NZAK? MP!MUU">2=K/Q!';PN_:-;5MJY]N?SJQ\%_A_HWCJ?66UD3M'9+"(UBEV9+E^ M3Q_L?K^0!]!W_C[0]+\&67BF^>X@T^\2-HE,6Z3YQD A<@'&>^..M>>-^TCH M'GD+H>I&'/#EHPQ'^[G'ZUYA\8KJ>T\7'PK'*YTG1(H8K*)CDHK01DY/<\5I MZ?!I[>&[6SE^&>I7),*%KQ-/F+R'@E@XD'!/I@8/I0!]#>$O&NB^-M/:[T>: M5M@4RQ2Q%&CW$@ ]B?E/0GI70U\O_!72O$^A_$JT,^CZG:6-U%+%-=*O=8T:&WL8O-E6X5R-P7C:P[D>HKGH])OM)\!WEO?0&*4 MW#R!=P;Y?*QG@GT->UA73^JJ%U=R5UUM<^?QJJK&.HD[1B[/I=H3P]?W&G>" M=1NY9Y1)([10EW)VGR\@@$_R]*98?\4WX&.KP8CO[PJBN?FZ.Q_#*C^55G'V MSX=+Y!QY-V-^.^(N?YU9UK][\,-):/YE25=Q'; /K$/\4[-5;E6B#8[<9_E3]G&K"$YJ[<'^ M%K,7M)T:DX4W9*I'\;W7H,AQ8?%ET4[4ED.X#OOCW?\ H1KT>O-[WYOBU& . M1)'G_OV#7I%>?F.JI/JX(]/*]'6BME-GG'QIEU6;P%/I>C6%_>75[+''(MI: MO+B+)8DE1QRH'X^]<%\%/AUJEM=W^L:K8WVFR_9YK2!ID,,D;,$_>*K+GH6 M;D=:]\O+VWT^!9KJ3RXVECA!VDY>1UC0<>K,H]L\\58KS3UCY[^(GP26ST6^ MUS2)-6U357N!+)$665I-[?,0JQ@DY.?IDU<^#VEZP?"?B#PAXAT?5+6UO0?L MYN;.2-07C8/\Y''W5(]SZFOY J52&4,.01D4 M ?%$GPZ\9Q7GV4^&-6+[@NY;1RG/^T!C'/7/%?7GA#PU:^$?#5MH]HH$<)=B M.ZC\.:NUN+FW;S5L92F $R<[<<8-? M5M^K/IUTJJ69HG &23@U8HH ^2OAMX/\3V'Q'T*ZO/#FKV]O%%'N%MG_>)*F%!1!S]T+]W)R">*^@J MKQ7MM/>7-I')NGMMOFIM(V[AD<]#QZ4 ?)M]XK^*GB:R_LF=M8N(74HT4-CL M+J1M(8H@)!!PQ?!_P"&EUX6T34W\001_:]358VB67=MAV\J<=&RQ!P3 MT&/?O=$F\.ZC)>R:/!:E[&Z>RN&CMO+*3)CV\>H0V#28N M9HI)HTVGE$*!CGIP9$_/V- 'RIJO@KQW\,_$,E[HD5\L#,XAN[(&;,0?(63 MQT5201@_G52_'Q,^)MS;VU]:ZC?"W/R!K4011ECC+$*J_B>< ^]?74T$-Q&8 MYXDE0]5=0P/X&H[:QL[+=]DM8+??C=Y487=CIG% 'AWQ"^'4VA?![3-$T'3; MN]N_[3BN;M+6-YR9/L[H[@ 9"Y [=_>K/[/.A:QHG_"2?VMI5]8>=]E\O[7; MO%OQYN<;@,XR.GJ*]PHH \2^-GPQN]''I MZ]110!%.9A&/(56;/.[T_.N0\,:W<>*(=4T[5&16,>T+&NU@K95O7ID?G7:5 MS%CX133_ !!/J<-XZI(2QCVCN^XC)[<#_&NS#SI*G.,]):6?F<.*A6=6G*GK M'7F7DT36NDZ+;6-WHEE<('N$%9$OX+SPOJI\I,?(N=K!E< MLP^N?Y4OBJP.BZK;Z[I1,D(;1-%URK:4'V*VBZK=>#]6 MFT_4(R+,DJ'9".F2&& $UU2NGYDT92E2="C:I3?1OEDO(6$^'?!RM>6EZ-1U#&P()1@<\_=!QQZ MYZ4WPEIMWK'B";7M0B=$(+QG;M5RV5X]@,_I^+I_#_A3P_(?[1O99YAQY+,0 M.?9!GH?6GZ=XLUW5M66/3M/1K2,']WC^'&!ESCN/:B3E.E*5*[;6LI::=D$% M&%6$*UDD](1UU[LBT>RN=6^(-[=WMO)&L)8E2I Z;%!_X#S[XK6/A^XA\<2: MY<2 VB@R%\ !<)M ZYX'?%5_&WB5(K8Z982I)A9(WGO)8@DH$8!C0]>!Z#C]:QE*M)0GI%37(EY=_Z\C>,:$'.&LG!\[? M][M_7GL:MA>:+JFIO+:R+)>0EMV-PQCY2>>#P?UK9KEO ND?8-!CN)4=;BX+ M.0W&%. !CW"@_C74UYF*C&-5P@VTM-3U\'*NGG^IS_C'_D!VW_85 MTW_TMAKH*YOQU;Q7?AE+:==\,VI:?&ZY(RIO(01D>U)_P@/AC_H&?^1Y?_BJ MYSJ+_B/_ ) X_P"OJV_]'I1J>KKI.EJT:)<7TD>+2S\T(]R_&%7KW(R<84') MXK!U?P;H&GV<-W:V'ESQ7=L4;SI#@^>G8MBJ7B*XU"#QOI$UAH?]JW%K9[[= M?M\=MM9PZOPP^?*@=.F/>@#>1_%KV9NF&G1RJ#_H)MV+,1_TU\[:,_[O%6O# MVN3:O!+'?V!TW4H"//LFE\PHK9V-NP P8 \CC((Z@UB?\)+XW_Z)]_Y6H?\ M"J5NOBS5_'>B:E?>&CI-G:K,ER_V^*?S R-LX'(PQ/3KNYZ4 =)K>NW%E,MC MI5B=0U)PK>2I(6)2<;G;&%& Y )&[80.:ANYO%=E;/&,HMO#$SK(C)(CNTGRLK $?*BL,CHV>F*;I/\ R-_B/_MV_P#19IEE!!'\ M0]:DC/[V73K(RK]'N0#^0Q^%/TG_ )&_Q'_V[?\ HLT ]\8/97UC M#:#Q5>^9%-9O(['*9PXE4#C ^Z<'GGI6]XGUJ#0_&.C3RJTDTNFWT-M"H),T MQDM2J9 .,D8R>!5#X6?\SK_V-=]_[)6_?1J_Q!T4L,[=,OB/KYMI0!&)_%YL M?M9M]/$VW/V#RB7SC./-\W;U^7[OO[5I:'K=OK=HSQ@Q7,)$=U;L#N@EQ\R< M@9P1HPZD!E[$@C^M7:*J,G%J2W)G!3BXRV9YGH%[>^&]4ET2]LWN8+EPF, M-C&[9N (P5(_/BG:GX7U'PS ?7;U'Y=J])VKN#;1N P# MCG'^17G^M2>(M!UZYU6'_2+>9BJQ@2,BC W 8&?QZYKV M?;;Y-W.WS81CVQBNETDH.#C*"?1>\CDC6 M.A*[(O*D4Y YP3[5E7?BO4-%'/\/05K0>&?#^GZ6=61 M;N\A*@A&$:/['H>CK!Z; 2=H]%0#'ZU%&$)?PH.7+UD M[)?(TKSJ1NZTU#FUM%7;^9:M=/L_ UN-4OY1=WT@"+ N!M)Y)!//3OCO[UL> M#M3U758I[J[2,6DDCM&3NW Y' SQM'(_"L;2? <]Y*+_ %FZ M+#^E>@)&D4:QQHJ(HPJJ, #V%;W?1>2.[+\/5NI6Y(+:.[?FV. MHHHKR3VC'\2V4U_I4$,"Y==0LIB,'[L=U$[=/]E36Q110!G:W;27>FB*(9;[ M1 _X+*C'] :JZMH?]H?8+V#RTU+3_FM7D' )V[E) W ,%VDCL>AZ5MT4 #<\2I<6=P&5)MN[#!USM;#') M*OG:HXQFJD'B+7+R7R(/#CP2MP)+J1TC7W)$?Z=SQQUKJ:* .8\/:!=:3X@U M2\N[K[7->PVYDG\LH"R&5<*"6P NSC<>23QD"K^G61Y9P>= MJ$&MBB@#E;'2;KPKJ%\^GVZWEEJM\]W,,E9(97/S' 4AEP!R<$$=\_+IW%G, M_C#3;U1^YAL+N%S@\,\EN5]ND;5KT4 %9<%K*GBG4+PC]S+96T2G!^\CSD_H MZUJ44 %%%% !1110 4444 %%%% !1110!1NM&TR])-S86\K$Y+-&,_GUK/D\ M%^'I&W-IJ@_[,CK_ "-;U%:QQ%6&D9-?-F$\-0F[S@GZI%>WLK:ULH[.*("W MC&U4;Y@!^-/@M;>U39;P10KC&(T"C]*EHJ'*3O=[FJA%6LM@HHHJ2@HHHH * J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9 end GRAPHIC 7 nrex99z2_1.jpg IMAGE begin 644 nrex99z2_1.jpg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end GRAPHIC 8 nrex99z3_1.jpg IMAGE begin 644 nrex99z3_1.jpg M_]C_X 02D9)1@ ! 0( #@ H #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ JA MJ>L66D0>;=3*.1@9'//.?:LV'P MQ;:4G]J>*K@2+)P8AO=BY]6!ZUZ5' I14Z[M?9+=GDU\Q;DZ>'2=MY-VBOF; MVD^.8-8UN+3X;*1%EW8D=QGA2>@^GK2>)?$>L:5?+#864QIU#-&FNYYVD1B-SJIY!8[< GC[PK3T/7;77K(7%N'0@E71 MQRI&._0]17C5*#5YT[N"=KV/?I8A/EA4LIM7M>YJ4445SG2%%%->18EW.<"@ M!U%1QS1R_<;./:I* "BBB@ HHJMJ%Y'IVFW5]*"8[:%YF"]2%!)Q^5 %FBO! M/#7Q\N]8\9V-A<:4T=I?7,5NJK.K&(M\N?N D;B#UKWN@ HHHH **** "BBB M@ HHHH **** "LS4M>T_2;J"WO)61Y_N80D=0.AQ- MXL\4W-]?,9;:V^==QP%&_*J?;&[BNS"8>-12G4?NQ7_#'!C<5.DX4Z2O*3TO MY;F[>6FA^#99-1>V$DDYQ!&%)VL,MU)./X>>V*P=.T.]U\G6M;NB+%LLNYBQ M;)VX 4_* 0/3M75:UX=M?$EW:78N_-BB(#JLHV%,Y.,#J?KZ5RE[/?>,=:?2 M]/=1IMN28P!L0*!@$XSWZ?7M7I86HY0NI>];WI/HNR\V>3BZ:A/EDRO/)"&Y&Z1$_0 M=/RI482IQI&K-0ASZ+54_A3ZZD4FM^+= VOJH+PGY0K-$3G MZ@$U.I\/^,U^RV]L-.U-OGWB+(..HRI&>!WQ71^+M8O-&T^&:TMUFW28DWQE MD"X/7!&.<8KF+S3-*\2Z>;SP]&(M30AIH%.S@\'CI[\'ZU5&<9P55QY&_M1V M_P"WEV%7IRISE04_:):\LMVO[K[^A7T_5+OPGJ4NF:SNN;$+L$8(=1CY@0#V MYZ<=?:M;3O"][9^*X]2TR6--+E_> @D91N=FT\_Y[&JVFSCQCI#Z/J!_XF5J M R2N-K<-AN>>V >/\:U]#L-,J,C/?/X48BHX*6T M9O22Z-/[2%A:2FX[R@O>B^J:^RV=917$>"=9NFOKO1]0F>2YC>1]TAR<@J", MD^NXUV]>/B*$J%1PD>]A<3'$TU4CH%?./[0OBR2?5X_"L1?R(%BN9N<#S"'X MQCGY64]?PKW_ %K5(-$T.^U2Y<+#:0/,Q/\ L@G'N3TQWKY0TC?\0_C=%/*# M<07FI&=PWR_Z.AW8/H B@?I6!T#_ (*:\=$^)>GQN[B"_#6CJO3+XV\?[RK7 MO_C3XL:'X$UB+3-5LM3EEE@$Z/;1QLI4DC^)P] 'LVG>+-,U3P@WBBV,QTT0RS$LF'VQE@W'_ #7&Z!\6C2Q1!1WR2)"< #T->+Z'\0%T[X,:WX6:Y9;V>8BV4(>(G M*;US[CS/SKN?V=O"L$EK?>);NU#3).(;*5NJX1A(5]B' S[>U ':/\;O"D/B M!M(N8=2MW0%GG>!3&H";_P"%RW3CA>OYT_0_C'X7\5ZN=&L[349#)&Y+30(( MV41L[ _/GHI'3_&OF[Q1;?;/B!+:YQYTL,>?3*H/ZU])Z3\)/"_A%I=3TU;P MW<,,NUYI]PY1E.1@#HQH \_\&ZU\);WQWIZZ1X7U.'4)9D^R-,/W<,@!^8CS MF'H?NG!&>M>P>+O'&B>"+);G6)9@TBL8H88B[R8(! _A'WAU(KY4^%?_ "5' MP]_U]C^1K:^(EU/XL^,J65[,\4$DUK:1B0[!"CA,]#/^$"=$\4O#XFT+ M58ELFNHX-*O/M#1RHK88KM&,\#WP/2@#L_&GQ>\/>"KU;"YBO+N]*EC%!& % M&2.68@=5(XS6%HO[0GA?4;L6]]9W^GEV"I(RB1#DXYVG(Z^AZ&O)?A'X1T_Q M]XPOH]>EEFCB@-RRB8J\SF1NZAK? MP!MUU">2=K/Q!';PN_:-;5MJY]N?SJQ\%_A_HWCJ?66UD3M'9+"(UBEV9+E^ M3Q_L?K^0!]!W_C[0]+\&67BF^>X@T^\2-HE,6Z3YQD A<@'&>^..M>>-^TCH M'GD+H>I&'/#EHPQ'^[G'ZUYA\8KJ>T\7'PK'*YTG1(H8K*)CDHK01DY/<\5I MZ?!I[>&[6SE^&>I7),*%KQ-/F+R'@E@XD'!/I@8/I0!]#>$O&NB^-M/:[T>: M5M@4RQ2Q%&CW$@ ]B?E/0GI70U\O_!72O$^A_$JT,^CZG:6-U%+%-=*O=8T:&WL8O-E6X5R-P7C:P[D>HKGH])OM)\!WEO?0&*4 MW#R!=P;Y?*QG@GT->UA73^JJ%U=R5UUM<^?QJJK&.HD[1B[/I=H3P]?W&G>" M=1NY9Y1)([10EW)VGR\@@$_R]*98?\4WX&.KP8CO[PJBN?FZ.Q_#*C^55G'V MSX=+Y!QY-V-^.^(N?YU9UK][\,-):/YE25=Q'; /K$/\4[-5;E6B#8[<9_E3]G&K"$YJ[<'^ M%K,7M)T:DX4W9*I'\;W7H,AQ8?%ET4[4ED.X#OOCW?\ H1KT>O-[WYOBU& . M1)'G_OV#7I%>?F.JI/JX(]/*]'6BME-GG'QIEU6;P%/I>C6%_>75[+''(MI: MO+B+)8DE1QRH'X^]<%\%/AUJEM=W^L:K8WVFR_9YK2!ID,,D;,$_>*K+GH6 M;D=:]\O+VWT^!9KJ3RXVECA!VDY>1UC0<>K,H]L\\58KS3UCY[^(GP26ST6^ MUS2)-6U357N!+)$665I-[?,0JQ@DY.?IDU<^#VEZP?"?B#PAXAT?5+6UO0?L MYN;.2-07C8/\Y''W5(]SZFOY J52&4,.01D4 M ?%$GPZ\9Q7GV4^&-6+[@NY;1RG/^T!C'/7/%?7GA#PU:^$?#5MH]HH$<)=B M.ZC\.:NUN+FW;S5L92F $R<[<<8-? M5M^K/IUTJJ69HG &23@U8HH ^2OAMX/\3V'Q'T*ZO/#FKV]O%%'N%MG_>)*F%!1!S]T+]W)R">*^@J MKQ7MM/>7-I')NGMMOFIM(V[AD<]#QZ4 ?)M]XK^*GB:R_LF=M8N(74HT4-CL M+J1M(8H@)!!PQ?!_P"&EUX6T34W\001_:]358VB67=MAV\J<=&RQ!P3 MT&/?O=$F\.ZC)>R:/!:E[&Z>RN&CMO+*3)CV\>H0V#28N M9HI)HTVGE$*!CGIP9$_/V- 'RIJO@KQW\,_$,E[HD5\L#,XAN[(&;,0?(63 MQT5201@_G52_'Q,^)MS;VU]:ZC?"W/R!K4011ECC+$*J_B>< ^]?74T$-Q&8 MYXDE0]5=0P/X&H[:QL[+=]DM8+??C=Y487=CIG% 'AWQ"^'4VA?![3-$T'3; MN]N_[3BN;M+6-YR9/L[H[@ 9"Y [=_>K/[/.A:QHG_"2?VMI5]8>=]E\O[7; MO%OQYN<;@,XR.GJ*]PHH \2^-GPQN]''I MZ]110!%.9A&/(56;/.[T_.N0\,:W<>*(=4T[5&16,>T+&NU@K95O7ID?G7:5 MS%CX133_ !!/J<-XZI(2QCVCN^XC)[<#_&NS#SI*G.,]):6?F<.*A6=6G*GK M'7F7DT36NDZ+;6-WHEE<('N$%9$OX+SPOJI\I,?(N=K!E< MLP^N?Y4OBJP.BZK;Z[I1,D(;1-%URK:4'V*VBZK=>#]6 MFT_4(R+,DJ'9".F2&& $UU2NGYDT92E2="C:I3?1OEDO(6$^'?!RM>6EZ-1U#&P()1@<\_=!QQZ MYZ4WPEIMWK'B";7M0B=$(+QG;M5RV5X]@,_I^+I_#_A3P_(?[1O99YAQY+,0 M.?9!GH?6GZ=XLUW5M66/3M/1K2,']WC^'&!ESCN/:B3E.E*5*[;6LI::=D$% M&%6$*UDD](1UU[LBT>RN=6^(-[=WMO)&L)8E2I Z;%!_X#S[XK6/A^XA\<2: MY<2 VB@R%\ !<)M ZYX'?%5_&WB5(K8Z982I)A9(WGO)8@DH$8!C0]>!Z#C]:QE*M)0GI%37(EY=_Z\C>,:$'.&LG!\[? M][M_7GL:MA>:+JFIO+:R+)>0EMV-PQCY2>>#P?UK9KEO ND?8-!CN)4=;BX+ M.0W&%. !CW"@_C74UYF*C&-5P@VTM-3U\'*NGG^IS_C'_D!VW_85 MTW_TMAKH*YOQU;Q7?AE+:==\,VI:?&ZY(RIO(01D>U)_P@/AC_H&?^1Y?_BJ MYSJ+_B/_ ) X_P"OJV_]'I1J>KKI.EJT:)<7TD>+2S\T(]R_&%7KW(R<84') MXK!U?P;H&GV<-W:V'ESQ7=L4;SI#@^>G8MBJ7B*XU"#QOI$UAH?]JW%K9[[= M?M\=MM9PZOPP^?*@=.F/>@#>1_%KV9NF&G1RJ#_H)MV+,1_TU\[:,_[O%6O# MVN3:O!+'?V!TW4H"//LFE\PHK9V-NP P8 \CC((Z@UB?\)+XW_Z)]_Y6H?\ M"J5NOBS5_'>B:E?>&CI-G:K,ER_V^*?S R-LX'(PQ/3KNYZ4 =)K>NW%E,MC MI5B=0U)PK>2I(6)2<;G;&%& Y )&[80.:ANYO%=E;/&,HMO#$SK(C)(CNTGRLK $?*BL,CHV>F*;I/\ R-_B/_MV_P#19IEE!!'\ M0]:DC/[V73K(RK]'N0#^0Q^%/TG_ )&_Q'_V[?\ HLT ]\8/97UC M#:#Q5>^9%-9O(['*9PXE4#C ^Z<'GGI6]XGUJ#0_&.C3RJTDTNFWT-M"H),T MQDM2J9 .,D8R>!5#X6?\SK_V-=]_[)6_?1J_Q!T4L,[=,OB/KYMI0!&)_%YL M?M9M]/$VW/V#RB7SC./-\W;U^7[OO[5I:'K=OK=HSQ@Q7,)$=U;L#N@EQ\R< M@9P1HPZD!E[$@C^M7:*J,G%J2W)G!3BXRV9YGH%[>^&]4ET2]LWN8+EPF, M-C&[9N (P5(_/BG:GX7U'PS ?7;U'Y=J])VKN#;1N P# MCG'^17G^M2>(M!UZYU6'_2+>9BJQ@2,BC W 8&?QZYKV M?;;Y-W.WS81CVQBNETDH.#C*"?1>\CDC6 M.A*[(O*D4Y YP3[5E7?BO4-%'/\/05K0>&?#^GZ6=61 M;N\A*@A&$:/['H>CK!Z; 2=H]%0#'ZU%&$)?PH.7+UD M[)?(TKSJ1NZTU#FUM%7;^9:M=/L_ UN-4OY1=WT@"+ N!M)Y)!//3OCO[UL> M#M3U758I[J[2,6DDCM&3NW Y' SQM'(_"L;2? <]Y*+_ %FZ M+#^E>@)&D4:QQHJ(HPJJ, #V%;W?1>2.[+\/5NI6Y(+:.[?FV. MHHHKR3VC'\2V4U_I4$,"Y==0LIB,'[L=U$[=/]E36Q110!G:W;27>FB*(9;[ M1 _X+*C'] :JZMH?]H?8+V#RTU+3_FM7D' )V[E) W ,%VDCL>AZ5MT4 #<\2I<6=P&5)MN[#!USM;#') M*OG:HXQFJD'B+7+R7R(/#CP2MP)+J1TC7W)$?Z=SQQUKJ:* .8\/:!=:3X@U M2\N[K[7->PVYDG\LH"R&5<*"6P NSC<>23QD"K^G61Y9P>= MJ$&MBB@#E;'2;KPKJ%\^GVZWEEJM\]W,,E9(97/S' 4AEP!R<$$=\_+IW%G, M_C#3;U1^YAL+N%S@\,\EN5]ND;5KT4 %9<%K*GBG4+PC]S+96T2G!^\CSD_H MZUJ44 %%%% !1110 4444 %%%% !1110!1NM&TR])-S86\K$Y+-&,_GUK/D\ M%^'I&W-IJ@_[,CK_ "-;U%:QQ%6&D9-?-F$\-0F[S@GZI%>WLK:ULH[.*("W MC&U4;Y@!^-/@M;>U39;P10KC&(T"C]*EHJ'*3O=[FJA%6LM@HHHJ2@HHHH * J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9 end GRAPHIC 9 nrex99z4_1.jpg IMAGE begin 644 nrex99z4_1.jpg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